Morgan Stanley’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-39,442
| Closed | -$583K | – | 8100 |
|
|
2024
Q1 | $583K | Sell |
39,442
-179,634
| -82% | -$2.52M | ﹤0.01% | 5240 |
|
|
2023
Q4 | $2.94M | Buy |
219,076
+125,899
| +135% | +$1.59M | ﹤0.01% | 4730 |
|
|
2023
Q3 | $1.15M | Buy |
93,177
+10,492
| +13% | +$127K | ﹤0.01% | 4718 |
|
|
2023
Q2 | $1.02M | Buy |
82,685
+28,525
| +53% | +$357K | ﹤0.01% | 4814 |
|
|
2023
Q1 | $666K | Buy |
54,160
+44,997
| +491% | +$529K | ﹤0.01% | 5092 |
|
|
2022
Q4 | $105K | Buy |
9,163
+2,649
| +41% | +$21.8K | ﹤0.01% | 5952 |
|
|
2022
Q3 | $25K | Sell |
6,514
-844
| -11% | -$3.9K | ﹤0.01% | 6705 |
|
|
2022
Q2 | $43K | Buy |
7,358
+1,235
| +20% | +$6.97K | ﹤0.01% | 6684 |
|
|
2022
Q1 | $39K | Buy |
6,123
+1,001
| +20% | +$5.62K | ﹤0.01% | 6826 |
|
|
2021
Q4 | $19K | Sell |
5,122
-706
| -12% | -$3.06K | ﹤0.01% | 7236 |
|
|
2021
Q3 | $28K | Sell |
5,828
-5,333
| -48% | -$27.8K | ﹤0.01% | 6973 |
|
|
2021
Q2 | $72K | Buy |
11,161
+5,218
| +88% | +$34.4K | ﹤0.01% | 6501 |
|
|
2021
Q1 | $38K | Buy |
5,943
+880
| +17% | +$6.29K | ﹤0.01% | 6484 |
|
|
2020
Q4 | $34K | Buy |
5,063
+1,231
| +32% | +$6.07K | ﹤0.01% | 6282 |
|
|
2020
Q3 | $15K | Buy |
3,832
+357
| +10% | +$1.31K | ﹤0.01% | 6155 |
|
|
2020
Q2 | $12K | Sell |
3,475
-4,428
| -56% | -$15.1K | ﹤0.01% | 6131 |
|
|
2020
Q1 | $17K | Sell |
7,903
-2,863
| -27% | -$8.37K | ﹤0.01% | 5877 |
|
|
2019
Q4 | $34K | Sell |
10,766
-21,606
| -67% | -$86.5K | ﹤0.01% | 5968 |
|
|
2019
Q3 | $146K | Buy |
32,372
+23,897
| +282% | +$119K | ﹤0.01% | 5303 |
|
|
2019
Q2 | $41K | Sell |
8,475
-1,612
| -16% | -$7.64K | ﹤0.01% | 5695 |
|
|
2019
Q1 | $55K | Buy |
10,087
+186
| +2% | +$855 | ﹤0.01% | 5626 |
|
|
2018
Q4 | $30K | Sell |
9,901
-10,425
| -51% | -$36.2K | ﹤0.01% | 5926 |
|
|
2018
Q3 | $86K | Sell |
20,326
-62,804
| -76% | -$265K | ﹤0.01% | 5733 |
|
|
2018
Q2 | $321K | Buy |
83,130
+34,555
| +71% | +$229K | ﹤0.01% | 5346 |
|
|
2018
Q1 | $307K | Buy |
48,575
+4,916
| +11% | +$40.7K | ﹤0.01% | 5273 |
|
|
2017
Q4 | $352K | Buy |
43,659
+9,263
| +27% | +$86.4K | ﹤0.01% | 5170 |
|
|
2017
Q3 | $393K | Sell |
34,396
-43,254
| -56% | -$455K | ﹤0.01% | 5015 |
|
|
2017
Q2 | $758K | Buy |
77,650
+39,445
| +103% | +$806K | ﹤0.01% | 4567 |
|
|
2017
Q1 | $925K | Sell |
38,205
-48,680
| -56% | -$1.22M | ﹤0.01% | 4439 |
|
|
2016
Q4 | $2.79M | Sell |
86,885
-27,050
| -24% | -$1.15M | ﹤0.01% | 3611 |
|
|
2016
Q3 | $5.69M | Buy |
113,935
+1,633
| +1% | +$67.8K | ﹤0.01% | 2539 |
|
|
2016
Q2 | $4.76M | Buy |
112,302
+1,025
| +0.9% | +$55.8K | ﹤0.01% | 2655 |
|
|
2016
Q1 | $7.33M | Sell |
111,277
-18,107
| -14% | -$945K | ﹤0.01% | 2143 |
|
|
2015
Q4 | $8.04M | Buy |
129,384
+6,457
| +5% | +$454K | ﹤0.01% | 2196 |
|
|
2015
Q3 | $8.23M | Buy |
122,927
+18,888
| +18% | +$1.54M | ﹤0.01% | 2167 |
|
|
2015
Q2 | $10.1M | Buy |
104,039
+3,745
| +4% | +$356K | ﹤0.01% | 2099 |
|
|
2015
Q1 | $9.38M | Sell |
100,294
-2,832
| -3% | -$241K | ﹤0.01% | 2113 |
|
|
2014
Q4 | $9.17M | Buy |
103,126
+8,616
| +9% | +$628K | ﹤0.01% | 2151 |
|
|
2014
Q3 | $6.53M | Buy |
94,510
+30,568
| +48% | +$1.63M | ﹤0.01% | 2402 |
|
|
2014
Q2 | $3.67M | Sell |
63,942
-43,014
| -40% | -$2.18M | ﹤0.01% | 2956 |
|
|
2014
Q1 | $4.24M | Sell |
106,956
-18,905
| -15% | -$809K | ﹤0.01% | 2728 |
|
|
2013
Q4 | $5.28M | Buy |
125,861
+119,080
| +1,756% | +$3.45M | ﹤0.01% | 2513 |
|
|
2013
Q3 | $202K | Sell |
6,781
-814
| -11% | -$28.5K | ﹤0.01% | 4885 |
|
|
2013
Q2 | $403K | Buy |
+7,595
| New | +$333K | ﹤0.01% | 4413 |
|
Other funds holding MACK
RA
JC
Morgan Stanley's MACK Position: Q2 2024 in Review
Morgan Stanley sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 39,442 shares — an estimated $583K sold.
Morgan Stanley first reported a position in MACK in Q2 2013 and held it in 44 quarters. The position peaked at $10.1M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Morgan Stanley reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Morgan Stanley sold 39,442 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $583K.
- Morgan Stanley first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 44 quarters.
- Morgan Stanley's Merrimack Pharmaceuticals, Inc. position peaked at $10.1M in Q2 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.